The fluid biomarkers of Alzheimer’s disease

Qinyu Peng, Zhentao Zhang

Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China

ARTICLE INFO
Received: 1 October, 2020
Revised: 2 December, 2020
Accepted: 24 December, 2020

© The authors 2021. This article is published with open access at journals.sagepub.com/home/BSA

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

KEYWORDS
 amyloid-β, tau, blood, cerebrospinal fluid, dementia

1 Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disease and the most common cause of dementia among people with old age. It is characterized by progressive cognitive dysfunction and behavioral impairments. More than 50 million patients have dementia worldwide, and this figure will have increased to 152 million by 2050 [1]. The diagnostic criteria of AD are constantly updated, especially the importance of biomarkers in disease diagnosis. However, few hospitals or research institutions in China can perform AD-related molecular imaging and cerebrospinal fluid (CSF) examination. Specific drugs that can effectively modify the development of AD pathology have yet to be developed. Most relevant clinical trials in developing new drugs have failed because initiating treatment is too late when patients show dementia. Thus, biomarkers that can facilitate the early diagnosis of AD should be developed.

AD has two major pathological characteristics.
of terms have invasive, the early composed of amyloid β (Aβ) and intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau. Neuronal loss, glial cell proliferation, and coexistence of other pathologies, such as TDP-43 or α-synuclein proteinopathies, occur in the brain of a patient with AD. AD pathologies exist many years before the appearance of the clinical symptoms of dementia. Hence, AD can be diagnosed at early stages by detecting the relevant biomarkers reflecting AD pathology. Currently, the generally recognized biomarkers used in AD diagnosis include PET (Aβ and tau) and core markers [Aβ, total tau (t-tau), and p-tau] in the CSF [3]. However, they are not widely applied in clinical practice because of their high cost and invasive procedures. Therefore, further studies have been performed to identify reliable, reproducible, inexpensive, noninvasive, sensitive, and specific fluid biomarkers to certain pathology.

This review is performed to summarize the established and emerging fluid biomarkers in different body fluids and highlight recent advances on their role in early diagnosis, progression monitoring, and correlations with AD pathology. Future prospects and related research direction are also discussed.

Relevant articles in English were identified for this review by searching PubMed without language restrictions for articles published before August 30, 2020. The following search terms were used: “Alzheimer Disease” “biomarker” “Aβ” “tau” “BACE1” “NF-L” “TREM2” “YKL-40” “neurogranin” “exosome (or EVs)” and “miRNA”.

2 Biomarkers in the CSF

The CSF directly associates with brain tissues. As such, biomarkers in the CSF can dynamically and sensitively reflect pathological changes. A cohort study has shown that the measured CSF biomarkers may be a reliable substitution for PET in AD diagnosis, and CSF tau/Aβ ratios are as precise as PET image evaluation in predicting outcomes read via a visual approach [4].

2.1 Aβ

Amyloid beta 42 (Aβ42), t-tau, and tau phosphorylated at threonine 181 (p-tau181) in the CSF are recognized as the core biomarkers in AD diagnosis. Aβ42, not p-tau181, in the CSF can differentiate amnestic mild cognitive impairment from subjective cognitive impairment; it can also predict progression from amnestic mild cognitive impairment to Alzheimer’s disease dementia [5, 6]. A comprehensive study has confirmed the discriminative performance of CSF Aβ42 between AD and other neurodegenerative diseases in the Chinese population [7]. Other studies have confirmed the CSF Aβ42/Aβ40 ratio can be used to predict the AD pathology with a higher accuracy than that of Aβ42 alone [8, 9], and it has a high reproducibility under different conditions of laboratory analysis [10]. The ratio has also been utilized to predict the progression from mild cognitive impairment (MCI) to AD [11]. Therefore, it shows a good performance in reducing quantitative variability caused by preanalytical factors, such as nonspecific sample tube adsorption, which can enhance the accuracy of CSF Aβ1-42 measurements [12].

2.2 tau

In a study on 322 participants from the ADNI cohort, an increase in CSF p-tau levels can indicate AD pathology and cognitive decline before tau PET abnormality occurs [13]. At the early stages of AD, increases in CSF t-tau and p-tau181 levels can reliably reflect pathological abnormalities and neuronal injury, but changes
in these two biomarkers have failed to show correlation with the pattern of brain atrophy and neurodegeneration at later disease stages [14]. In another study based on a large cohort, the correlation of tau PET with CSF p-tau217 is significantly stronger than that with CSF p-tau181 in brain regions corresponding to the Braak stage; this finding suggests that CSF p-tau217 is a more significantly accurate predictor of an aberrant tau PET status than CSF p-tau181. CSF p-tau217 can also be used to distinguish AD from other neurodegenerative diseases. Moreover, the longitudinal increase in CSF p-tau217 is higher than that in CSF p-tau181 and better interrelated with tau PET in Aβ-positive individuals. Another cohort study has provided consistent evidence supporting the better performance of CSF p-tau217 in the differential diagnosis of AD [15, 16].

In a study on three independent cohorts, a tangle-enriched fragment of tau generated by the cysteine protease asparagine endopeptidase is introduced and named tauN368; its qualitative analysis in the CSF via a novel Simoa method suggests the fragmentation patterns change in AD, as indicated by a higher CSF tauN368 level but a lower CSF tau368/t-tau in patients with AD than in the controls [17]. In another large cohort study by Dr. Blennow and his team, t-tau/Aβ42 and p-tau/Aβ42 are used to predict the risk of clinical decline and conversion to dementia in patients without dementia [18]. Interestingly, vascular risk factors are correlated with longitudinal changes in CSF tau markers [19]. Accordingly, a more sensitive, fast, and simple technique for tau detection should be developed. And it is noteworthy that a transistor-based biosensor with the direct label-free detection of tau is presented [20].

2.3 BACE1

β-site amyloid precursor protein cleaving enzyme 1 (BACE1) mediates the rate-limiting step during Aβ production. It is widely expressed in the brain, particularly in neurons, oligodendrocytes, and astrocytes [21–23]. It is the major β-secretase that participates in the sequential proteolytic processing of amyloid precursor protein (APP) and the generation of Aβ [24]. Several studies have focused on BACE1 levels in the CSF. The BACE1 activity in patients with MCI-AD is higher than that in controls and MCI-non-AD [25]. The ratio of neurogranin and BACE1 in the CSF has also been studied as a potential marker of synapse loss in early AD. Neurogranin is linked to postsynaptic signal transduction, and BACE1 is associated with presynaptic APP metabolism. A cohort study has demonstrated that a higher level of CSF neurogranin/BACE1 in preclinical AD is related not only to the reduction of hippocampal volume and memory function at baseline but also to the cognitive decline during follow-up [26]. Besides, the neurogranin/BACE1 ratio in CSF can be used to discriminate patients diagnosed with a major depressive disorder and cognitive impairments from patients with mild AD [27].

2.4 NF-L

Neurofilament light chain (NF-L), which is an abundant cytoskeletal protein exclusively expressed by central and peripheral neurons, is a prospective biomarker of active neuroaxonal damage and neurodegeneration [28, 29]. In a research involving 467 subjects from a multicenter study, CSF NF-L levels increase with age, and this result is independent of diagnosis, but it is contrary to the trajectory of CSF tau markers that decrease at the late stage of AD [30]. Importantly, CSF NF-L is a strong predictor of cognitive decline in the AD spectrum [31, 32]. Increased CSF NF-L levels may be correlated with damage to the white matter in prodromal
AD [33, 34]. In another research based on 221 participants, CSF NF-L levels are significantly elevated in patients with AD compared with that in healthy controls and could differentiate individuals with AD from controls with a sensitivity of 81.5%. In particular, CSF NF-L levels can be utilized to predict volume loss in the cortical gray matter and cognitive decline; therefore, it is a promising biomarker of neurodegeneration during disease progression [32]. However, NF-L may be a nonspecific biomarker of axonal degeneration because its level increases in a majority of neurodegenerative diseases [35–37]. Thus, CSF NF-L should be combined with other disease-specific biomarkers in the analysis of AD diagnosis.

2.5 TREM2

Triggering receptor expressed on myeloid cell 2 (TREM2), which is expressed abundantly by microglia in the central nervous system (CNS), is an important microglial regulator. It enables microglial responses by sustaining energetic and biosynthetic metabolism in cells in AD [38]. High levels of CSF sTREM2 are correlated with the biomarkers of tau and neuronal injury in CSF but not in amyloidosis [39–41]. Interestingly, high CSF sTREM2 levels at baseline are associated with slow rates of Aβ accumulation (assessed with amyloid PET for more than 2 years); this result suggests that high CSF sTREM2 levels play a protective role in the progression of amyloid pathology [42]. Another study has proposed similar protective effects of TREM2 at the preclinical stage of AD and provided evidence that blood TREM2 levels in patients with MCI and particularly those with MCI-AD are higher than those in healthy controls [43]. A longitudinal study has confirmed that CSF sTREM2 at baseline is associated with longitudinal volumetric and diffusivity changes in AD-related regions [44].

2.6 YKL-40

CSF chitinase-3-like protein 1 (YKL-40) is a secreted glycoprotein expressed by microglia and astrocytes in the CNS [45, 46] and considered one of the most promising biomarkers of neuroinflammation in AD. In a longitudinal study, CSF YKL-40 increases with age [30]. In a study on participants from the ADNI database, YKL-40 can be used to reflect neurodegeneration and is associated with hippocampal atrophy at baseline and follow-up in Aβ-positive patients [47]. In another study on participants from two Norwegian cohorts, CSF YKL-40 levels increase in patients with dementia-related AD compared with Aβ-positive MCI individuals and healthy controls [48]. A large cohort study has confirmed that CSF YKL-40 levels increase in preclinical AD. It is associated with tau pathology in Aβ-positive individuals. A high YKL-40 level is correlated with cognitive impairment and a high risk of progression to AD [49]. CSF YKL-40 is related to progression from presymptomatic to symptomatic AD [50].

2.7 Neurogranin

Neurogranin is a calmodulin-binding postsynaptic protein that plays a critical role in synaptic plasticity and long-term potentiation [51]. The trajectory of CSF neurogranin increases with aging in Aβ-positive individuals [52]. It is also significantly associated with AD pathology [31, 53]. In a study based on patients from the ADNI database, CSF neurogranin levels are associated with CSF core biomarkers, and the diagnostic efficiency of neurogranin in differentiating AD from controls is comparable with that of core biomarkers in the CSF. Neurogranin levels also increase in MCI and AD groups compared with those in the control group, and this increase can be used to predict the conversion from cognitively normal to MCI.

https://mc03.manuscriptcentral.com/brainsa | Brain Science Advances
Importantly, high levels of CSF neurogranin are correlated with longitudinal cognitive decline [54]. Other studies have also confirmed the correlation of CSF neurogranin with cognitive decline in AD [55, 56].

3 Biomarkers in the blood

Undergoing an invasive lumbar puncture in CSF collection is not widely acceptable among patients. Instead, collecting blood specimens is preferred because this procedure is noninvasive, convenient, reproducible, and cost effective. Some molecules can pass the blood–brain barrier, so some biomarkers in the blood can reflect the AD pathology.

3.1 Aβ

Notably, a novel measurement of plasma Aβ biomarkers via immunoprecipitation coupled with mass spectrometry has demonstrated the potential clinical practicality of blood biomarkers in predicting brain Aβ burden [57]. Plasma Aβ 40/42 ratio can also predict cerebral amyloidosis in cognitively normal individuals at risk of AD [58]. The plasms Aβ42/Aβ40 ratio also shows a good performance in the differential diagnosis [59] and identification of AD pathology in cognitively normal individuals with SCD [60]. Many studies have demonstrated that a low Aβ42/Aβ40 ratio is associated with diagnosis and PET Aβ positivity in AD, indicating that this ratio can be utilized to predict cerebral Aβ deposition [61, 62]. In another cohort study, plasma Aβ42/Aβ40 is applied to identify individuals suffering from amnestic MCI and predict its progression to dementia [63].

3.2 Aβ oligomers

In AD, Aβ is initially transformed into oligomers and fibrils and subsequently into amyloid plaques. Among them, oligomeric Aβ is the main toxic species. Amazingly, there are quite a few studies have developed novel effective approaches for Aβ oligomer detection in recent years [64–67]. The increased levels of oligomeric Aβ measured with a multimer detection system (also called MDS-OAβ) in the blood are negatively correlated with changes in the volume of specific brain regions, especially the typical areas of degeneration in AD [68]. Interestingly, compared with healthy controls, a stronger association between increased plasma levels of oligomeric Aβ, and deduced general cognitive level, particularly episodic memory performance is observed in patients with AD [69].

3.3 tau

In a recent prospective study, plasma t-tau is correlated with the risk of AD and the improved risk stratification of dementia after adjustments for age and sex. A marked increase in plasma t-tau levels is associated with cognitive decline, a small hippocampal volume (measured via MRI), a high burden of neurofibrillary tangles, and microinfarcts during autopsy [70]. By contrast, a clear association between plasma t-tau and AD risk is not found in two large cohort studies [60, 71]. These contradictory results may indicate that plasma t-tau is not a specific biomarker. In a longitudinal study, increased levels of tau-related biomarkers in plasma (p-tau, t-tau, p-tau/Aβ42, and t-tau/Aβ42) are significantly correlated with brain tau deposition and a high risk of tau PET positivity. Notably, the brain regions associated with increased plasma t-tau/Aβ1-42 resemble the typical region characterized by neurofibrillary tangles in AD. Particularly, plasma t-tau/Aβ1-42 can predict brain tau accumulation and neuropathological changes [72].
Plasma p-tau may serve as an accurate biomarker of AD. In four clinic-based cohorts, plasma p-tau181 gradually enhances along the AD continuum, shows a correlation with tau and Aβ pathologies (measured via PET), and plays a role in the differential diagnosis of AD from other neurodegenerative diseases [73]. These results are consistent with data from Mayo Clinic [74]. In a longitudinal cohort, plasma p-tau181 can be used to distinguish patients with AD pathology from controls without AD pathology with an AUC of 97.4% [75]. These studies have demonstrated the sensitivity and specificity of plasma p-tau181 as a biomarker of AD pathology. In addition, p-tau217 and p-tau181 in plasma are related to their concentrations in CSF. Importantly, p-tau217 has the highest specification for amyloid plaque status [76] and is used to accurately discriminate AD from other neurodegenerative diseases [77]. These studies have emphasized the importance of plasma p-tau in AD diagnosis.

3.4 BACE1

Andrea Vergallo et al. proposed the sexual dimorphism of plasma BACE1 and provided evidence that its mean concentrations are significantly higher in women than in men in cross-sectional and longitudinal aspects [78]. In a cohort of cognitively normal individuals at risk for AD, plasma BACE1 levels are associated with Aβ PET at baseline. In another study, a sensitive and specific assay is developed to detect the activity of human plasma BACE1 and quantify its protein expression [79]. In 224 individuals from three independent international academic AD research centers and memory clinics, \( V_{\text{mean}} \) of the plasma BACE1 activity in patients with MCI nonconverters (patients with MCI that has not converted to probable AD), MCI converters, and AD increases by 45.0%, 85.4%, and 97.3%, respectively, compared with those in healthy controls. Besides, the BACE1 activity is higher in MCI converters than in MCI nonconverters, indicating the utility of plasma BACE1 in predicting progression from prodromal AD to probable AD dementia [79]. Furthermore, a larger population-based study has found that the serum BACE1 activity significantly increases by around 25% in patients with late-onset AD compared with that in healthy controls [80].

3.5 NF-L

Plasma NF-L levels in patients with AD at the dementia stage and patients with MCI and a high prospect of underlying AD pathology (MCI-AD) significantly increase compared with those in controls without dementia even after adjustments for age are made [81]. Plasma NF-L concentrations are negatively correlated with cognitive status [81]. High NF-L plasma levels and low Aβ42 levels are each independently and in combination strongly correlated with the risk of all-cause and AD dementia [71].

An increased plasma NF-L may also be used to predict changes in the white matter [82, 83]. A study from the world’s largest single-mutation autosomal dominant AD characterized plasma NF-L concentrations based on 2,144 presenilin 1 (PSEN1) E280A mutation carriers and noncarriers. It reported that plasma NF-L increases with age in all groups (cognitively impaired carriers, unimpaired carriers, and noncarriers). Interestingly, plasma NF-L concentrations can be used to significantly discriminate carriers from noncarriers at 22 years (22 years before the carriers’ predicted age of 44 years at the MCI onset). Plasma NF-L levels are also associated with a low cognitive function at baseline and a large cognitive decline during the follow-up of approximately 6 years [84].
3.6 EVs

Extracellular vesicles (EVs), including exosomes and (shedding) microvesicles, can transport cargo (e.g., proteins and nucleic acids) between cells as a form of intercellular communication. CNS- or brain-derived extracellular vesicles likely play a critical role in biomarker research and therapeutic research because of its extraordinary characteristic of traveling between the CNS and peripheral circulation. Recently, a large longitudinal cohort study has provided evidence that the longitudinal trajectory of neuronal-enriched EV biomarkers in patients with future AD is different from those in controls with reliance on age and sex. Importantly, the cohort study also validated the usefulness of a model based on several EV biomarkers in the prediction of preclinical AD with high accuracy [85]. The levels of EV biomarkers (t-tau, p-tau181, and p-tau231) in older individuals with cognitive impairment milder than MCI are higher than those in patients with stable cognition. The annualized rates of change in insulin signaling biomarkers are also higher in individuals with cognitive decline than in patients with stable cognitive ability. These results indicate the potency of EV biomarkers in identifying the tau pathology or cognitive decline prior to clinical AD [86].

With regard to core biomarkers in EVs, a multicenter study has confirmed the correlation of exosomal biomarkers with those in the CSF and demonstrated that Aβ42, t-tau, and p-tau181 in exosomes can be used for the diagnosis of AD and aMCI considered useful as those in CSF [87]. Interestingly, the abnormal levels of APP and p-tau181/t-tau in EVs may identify patients with MCI [88]. As for exosomal synaptic proteins, Jia et al. demonstrated the robust association of some synaptic protein levels in EVs and CSF and the usefulness of the combination of exosomal GAP43, neurogranin, SNAP25, and synaptotagmin 1 in determining preclinical AD 5–7 years before cognitive impairment [89]. Furthermore, exosomal synaptic proteins are correlated with cognitive decline and may indicate the progression of AD as their levels decrease [90, 91]. In terms of exosomal microRNAs (miRNAs), the concentrations of two miRNAs (hsa-miR-451a and hsa-miR-21-5p) in AD significantly decreased compared with that in DBL with an AUC of 0.9; this result suggests its potential performance in the differential diagnosis of AD from DBL [92].

3.7 miRNA

miRNAs, as endogenous regulators of gene expression, are small noncoding RNA molecules widely expressed in the nervous system. In a large systematic review on data from 147 independent data sets, 25, 5, and 32 miRNAs have a significant differential expression in the brain, CSF, and blood-derived specimens, respectively [93]; furthermore, 36 repeatedly differential blood miRNAs may be promising components of the diagnostic panel of AD [94]. Blood miR-146b-5p and miR-15b-5p have a unanimous differential expression in AD compared with that in the controls [95]. A plasma-based panel composed of miRNAs correlated with synaptic proteins (miR-92a-3p, miR-181c-5p, and miR-210-3p) yields a high diagnosis accuracy of 0.893 for distinguishing subjects with MCI and AD from healthy controls and can be used to predict the progression of MCI to AD [96]. Hsa-mir-567 can be utilized to determine cognitive decline and predict MCI progression to AD with its higher serum expression in MCI-AD (MCI due to AD) and AD groups than in healthy controls [97]. Interestingly, Jain et al. defined a suitable panel consisting of three miRNAs to detect AD with an AUC of 0.83 in a replication cohort [98]. However, the performance of miRNAs as...
biomarkers of AD is neither consistent nor validated in a longitudinal independent cohort. Thus, cohort studies with standard procedures should be performed.

4 Biomarkers in the urine and saliva

Recently, a multicenter study based on two cohorts has demonstrated that salivary lactoferrin (Lf) can discriminate prodromal AD and AD dementia from healthy controls with a high accuracy. It distinguishes AD from FTD with a sensitivity of 87% and a sensitivity of 91%. Reduced Lf levels can be used to identify subjects with positive cerebral amyloidosis [99], and this finding is consistent with a previous study [100]. Bermejo-Pareja et al. hypothesized that the reduced levels of salivary (Lf) may be related to immunological disturbances in AD, and this observation agrees with the physiopathological explanations of AD [101]. In a pilot study, a targeted and quantitative metabolomics approach is applied, and several panels composed of urinary metabolites are identified to distinguish MCI and AD from cognitively healthy controls with high sensitivity and specificity [102]. Several novel urinary biomarkers for the early diagnosis of AD have been discovered, and some of them are Alzheimer-associated neuronal thread protein (AD7c-NTP) [103–106], monocyte chemoattractant protein-1 (MCP-1) [107], and dysregulated arginine metabolism [108].

5 Conclusions

AD is a destructive neurodegenerative disorder characterized by complicated pathological changes and clinical manifestations. Patients who are pathologically confirmed to have AD only account for three-fourths of patients who are clinically diagnosed with AD [109]. As such, reliable biomarkers that can contribute to the accurate early diagnosis of AD must be developed. Currently, extensively validated core biomarkers include Aβ42, t-tau, and p-tau in the CSF. These core CSF biomarkers sensitively and reliably reflect AD pathology. However, their clinical application is less satisfactory because of invasive procedures. Conversely, biomarkers in the blood show potential for application in the early diagnosis of AD. The most promising biomarkers in the blood are plasma p-tau217, p-tau181, and NF-L. Other potential biomarkers, such as plasma BACE1, TREM2, YKL-40, neurogranin, and EVs, should be further validated. More details with those selected candidates of AD fluid biomarkers are summarized in Table 1. Conditions and protocols should be standardized to enhance the accuracy of measurements [110–112]. Larger cohort studies should also be performed to demonstrate the correlation of different biomarkers in the blood with those in the CSF and thus improve their accuracy. More longitudinal studies should be carried out to validate the clinical utility of these biomarkers.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 81822016, No. 81771382) to Zhentao Zhang.

Conflict of interests

All contributing authors have no conflict of interests to declare.
| Biomarkers | Associated pathology | Levels in AD vs. healthy controls | Discriminative performance | Prediction of AD pathology | Correlation with neurodegeneration | Prediction of disease progression | Correlation with cognitive decline | Other |
|------------|----------------------|----------------------------------|----------------------------|----------------------------|----------------------------------|---------------------------------|---------------------------------|-------|
| In CSF     | Aβ                   | Aβ pathology                      | i                          | aMCI vs. SCI [6] AD vs. other neurodegenerative diseases [7] | From aMCI to ADD [5] |                                  |                                  |       |
|            | Aβ42/Aβ40            |                                  | i                          | With higher accuracy than Aβ42 alone [8, 9] | From MCI to AD [11] | Good performance in reducing the quantitative variability [12] |                                  |       |
| tau        | p-tau                | tau pathology                     | †                          | Predict the AD pathology before tau PET abnormality [13] |                                  |                                  | † [13] |       |
|            | p-tau217             |                                  | †                          | A better predictor of aberrant tau PET status than CSF p-tau181 [15] |                                  |                                  |                                  |       |
|            | tauN368              |                                  | †                          | CSF tau368/t-tau reflects tangle pathology [17] |                                  |                                  |                                  |       |
|            | t-tau/Aβ42 p-tau/Aβ42|                                  | †                          | Conversion to dementia in patients without dementia [18] | † [18]                      |                                  |                                  |       |
| BACE1      |                       |                                  | †                          | Neurogranin/BACE1 ratio in CSF discriminates patients diagnosed with major depressive disorder and cognitive impairments from patients with mild AD [27] | A higher level of CSF neurogranin/BACE1 in preclinical AD was associated with the reduction of hippocampal volume [26] | † [26] |                                  |       |
| NF-L       | Neuroaxonal damage and neurodegeneration | †                          | AD vs. healthy controls [32] | May correlate with damage to the white matter in prodromal AD [32-34] |                                  |                                  | † [31, 32] | Nonspecific biomarker observed in a majority of neurodegenerative diseases [35-37] |
| TREM2      | Neuroinflammation response | Dynamic change [40] | Higher CSF sTREM2 levels at baseline were associated with slower rates of Aβ accumulation [42] |                                  |                                  |                                  | Early increase in sTREM2 is associated with tau-related neurodegeneration but not with amyloid-β pathology [41] showing protective effects in the preclinical stage of AD [43] |
| YKL-40    | Neuroinflammation    | †                          | Associated with tau pathology in Aβ-positive individuals [49] | Associated with hippocampal atrophy [47] | From presymptomatic to symptomatic AD [50] |                                  | † [49] |       |
| Neurogranin| Synaptic dysfunction | †                          | AD vs. healthy controls comparable efficiency to that of core biomarkers in CSF [54] | Significantly associated with the degree of amyloid and tau pathology [53] | From cognitively normal to MCI [54] |                                  | † [54-56] |       |
| Biomarkers | Levels in blood | AD pathology vs healthy controls | Associated with pathology | Prediction of AD progression | Correlation with neurodegeneration | Other |
|------------|----------------|---------------------------------|--------------------------|-----------------------------|---------------------------------|-------|
| Aβ Aβ42/Aβ40 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| t-tau | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| p-tau181 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| p-tau123 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| BACE1 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| NfL | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| p63 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| miRNA | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |

**Note:**
- ↑ indicates an increase in levels.
- ↓ indicates a decrease in levels.
- Other elements such as Aβ, t-tau, p-tau, and BACE1 are associated with AD pathology.
- NfL levels are predictive of AD progression.
- Correlation with neurodegeneration includes changes in specific regions of the brain.

**References:**
- [1] "Brain Sci. Adv. 10, 2021."
References

[1] World Alzheimer Report 2019 Attitudes to dementia. https://www.alz.co.uk/research/WorldAlzheimerReport2019-Summary.pdf (accessed 1 Sep, 2020)

[2] Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat Neurosci 2015, 18(6): 800–806.

[3] Blennow K, Leon MJ de L, Zetterberg H. Alzheimer's disease. Lancet 2006. 368(9533): 387–403.

[4] Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's Dement 2018, 14(11): 1470–1481.

[5] Rizzi L, Missiaggia L, Roriz-Cruz M. CSF Aβ1-42, but not p-Tau181, predicted progression from amnestic MCI to Alzheimer's disease dementia. NeuroMolecular Med 2018, 20(4): 491–497.

[6] Rizzi L, Maria PM, Batista CEA, et al. CSF Aβ1-42, but not p-Tau181, differentiates aMCI from SCI. Brain Res 2018, 1678: 27–31.

[7] Ye LQ, Li XY, Zhang YB, et al. The discriminative capacity of CSF β-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population. J Neurol Sci 2020, 412: 116756.

[8] Baiardi S, Abu-Rumeileh S, Rossi M, et al. Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias. Ann Clin Transl Neurol 2018, 6(2): 263–273.

[9] Lehmann S, Delaby C, Boursier G, et al. Relevance of Aβ42/40 Ratio for detection of Alzheimer disease pathology in clinical routine: The PLMβ Scale. Front Aging Neurosci 2018, 10: 138.

[10] Vogelsgang J, Wedekind D, Bouter C, et al. Reproducibility of Alzheimer's disease cerebrospinal fluid-biomarker measurements under clinical routine conditions. J Alzheimers Dis 2018, 62(1): 203–212.

[11] Baldeiras I, Santana I, Leitão MJ, et al. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Alzheimers Res Ther 2018, 10(1): 33.

[12] Schauer SP, Mylott WR, Jr., Yuan M, et al. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays. Alzheimers Res Ther 2018, 10(1): 118.

[13] Meyer PF, Binette AP, Gonneaud J, et al. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated Tau and AV1451 positron emission tomography. JAMA Neurol 2020, 77(4): 508–516.

[14] Llibre-Guerra JJ, Li Y, Schindler SE, et al. Association of longitudinal changes in cerebrospinal fluid total tau and phosphorylated tau 181 and brain atrophy with disease progression in patients with Alzheimer disease. JAMA Netw Open 2019, 2(12): e1917126.

[15] Barthélémy NR, Bateman RJ, Hirtz C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimers Res Ther 2020, 12(1): 26.

[16] Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun 2020, 11(1): 1683.

[17] Blennow K, Chen C, Cicognola C, et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain 2020, 143(2): 650–660.

[18] Blennow K, Shaw LM, Stomrud E, et al. Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ1-42, pTau and tTau CSF immunoassays. Alzheimers Res Ther 2019, 9(1): 19024.

[19] Bos I, Vos SJB, Schindler SE, et al. Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer’s disease. Alzheimers Dement 2019, 15(9): 1149–1159.

[20] García-Chamé M, Gutiérrez-Sanz Ó, Ercan-Herbst E, et al. A transistor-based label-free immunosensor for rapid detection of tau protein. Biosens Bioelectron
and astroglial activation across the clinical Alzheimer's disease spectrum. *Alzheimers Dement* 2019, 15(5): 644–654.

[32] Dhiman K, Gupta VB, Villemagne VL, et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. *Alzheimers Dement (Amst)* 2020, 12(1): e12005.

[33] Andersson E, Janelidze S, Lampinen B, et al. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. *Neurobiol Aging* 2020, 95: 143–153.

[34] Moore EE, Hohman TJ, Badami FS, et al. Neurofilament relates to white matter microstructure in older adults. *Neurobiol Aging* 2018, 70: 233–241.

[35] Rojas JC, Bang J, Lobach IV, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. *Neurology* 2018, 90(4): e273–e281.

[36] Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. *Ann Neurol* 2014, 75(1): 116–126.

[37] Skillbäck T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. *Neurology* 2014, 83(21): 1945–1953.

[38] Ulland TK, Song WM, Huang SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. *Cell* 2017, 170(4): 649–663.e13.

[39] Rauchmann BS, Schneider-Axmann T, Alexopoulos P, et al. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. *Neurobiol Aging* 2019, 74: 182–190.

[40] Ma LZ, Tan L, Bi YL, et al. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study. *Mol Neurodegener* 2020, 15(1): 25.

[41] Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, et al. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. *Mol Neurodegener* 2019, 14(1): 1.

[42] Ewers M, Biechele G, Suárez-Calvet M, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation.
EMBO Mol Med 2020, 12(9): e12308.

[43] Casati M, Ferri E, Gussago C, et al. Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease. Eur J Neurol 2018, 25(6): 805–810.

[44] Falcon C, Monté-Rubio GC, Grau-Rivera O, et al. CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. Neuroimage Clin 2019, 23: 101801.

[45] Cantó E, Tintoré M, Villar LM, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015, 138(Pt 4): 918–931.

[46] Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, et al. YKL40 (Chitinase 3-like 1) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. J Neuroinflammation 2017, 14(1): 118.

[47] Zhang H, Ng KP, Therriault J, et al. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. Transl Neurodegener 2018, 7: 23.

[48] Nordengen K, Kisseljov BE, Henjum K, et al. Glial activation and inflammation along the Alzheimer's disease continuum. J Neuroinflammation 2019, 16(1): 46.

[49] Janelidze S, Mattsson N, Stomrud E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 2018, 91(9): e867–e877.

[50] Thordardottir S, Almkvist O, Johansson C, et al. Cerebrospinal fluid YKL-40 and neurogranin in familial Alzheimer's disease: a pilot study. J Alzheimers Dis 2020, 76(3): 941–953.

[51] Gerendasy DD, Sutcliffe JG. RC3/neurogranin, a postsynaptic calpain for setting the response threshold to calcium influxes. Mol Neurobiol 1997, 15(2): 131–163.

[52] Milà-Alomà M, Salvadó G, Gispert JD, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimers Dement 2020, 16(10): 1358–1371.

[53] Kvartsberg H, Lashley T, Murray CE, et al. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. Acta Neuropathol 2019, 137(1): 89–102.

[54] Xue M, Sun FR, Ou YN, et al. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease. Aging (Albany NY) 2020, 12(10): 9365–9379.

[55] Headley A, De Leon-Benedetti A, Dong CH, et al. Neurogranin as a predictor of memory and executive function decline in MCI patients. Neurology 2018, 90(10): e887–e895.

[56] Liu WL, Lin HW, He XJ, et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment. Transl Psychiatry 2020, 10(1): 125.

[57] Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature 2018, 554(7691): 249–254.

[58] Vergallo A, Mégre L, Lista S, et al. Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimers Dement 2019, 15(6): 764–775.

[59] Vogelsang J, Shahpasand-Kroner H, Vogelsang R, et al. Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease. Exp Brain Res 2018, 236(5): 1241–1250.

[60] Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 2018, 84(5): 648–658.

[61] Pérez-Grijalba V, Arbizu J, Romero J, et al. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alzheimers Res Ther 2019, 11(1): 96.

[62] Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA neurol 2019, 76(9): 1060–1069.

[63] Pérez-Grijalba V, Romero J, Pesini P, et al. Plasma Aβ42/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging
biomarkers in the AB255 study. J Prev Alzheimers Dis 2019, 6(1): 34–41.

[64] Amouzadeh Tabrizi M, Ferré-Borrull J, Marsal LF. Highly sensitive aptasensor based on interferometric reflectance spectroscopy for the determination of amyloid β as an Alzheimer's disease biomarkers using nanoporous anodic alumina. Biosens Bioelectron 2019, 137: 279–286.

[65] Chen WL, Gao G, Jin Y, et al. A facile biosensor for Aβ40 based on fluorescence quenching of Prussian blue nanoparticles. Talanta 2020, 216: 120930.

[66] Yin YM, Chen GF, Gong L, et al. DNAzyme-powered three-dimensional DNA walker nanoprobe for detection amyloid β-peptide oligomer in living cells and in vivo. Anal Chem 2020, 92(13): 9247–9256.

[67] Zhao YN, Li X, Yang Y, et al. A simple aptasensor for Aβ40 oligomers based on tunable mismatched base pairs of dsDNA and graphene oxide. Biosens Bioelectron 2020, 149: 111840.

[68] Youn YC, Lee BS, Kim GJ, et al. Blood amyloid-β oligomerization as a biomarker of Alzheimer's disease: a blinded validation study. J Alzheimers Dis 2020, 75(2): 493–499.

[69] Meng X, Li T, Wang X, et al. Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer's disease. Alzheimers Res Ther 2019, 11(1): 89.

[70] Pase MP, Beiser AS, Himali JJ, et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol 2019, 76(5): 598–606.

[71] De Wolf F, Ghanbari M, Licher S, et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain 2020, 143(4): 1220–1232.

[72] Park JC, Han SH, Yi D, et al. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. Brain 2019, 142(3): 771–786.

[73] Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020, 19(5): 422–433.
[84] Quiroz YT, Zetterberg H, Reiman EM, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. *Lancet Neurol* 2020, **19**(6): 513–521.

[85] Kapogiannis D, Mustapic M, Shardell MD, et al. Association of extracellular vesicle biomarkers with Alzheimer disease in the Baltimore Longitudinal Study of Aging. *JAMA Neurol* 2019, **76**(11): 1340–1351.

[86] Eren E, Hunt JFV, Shardell M, et al. Extracellular vesicle biomarkers of Alzheimer's disease associated with sub-clinical cognitive decline in late middle age. *Alzheimers Dement* 2020, **16**(9): 1293–1304.

[87] Jia LF, Qiu QQ, Zhang H, et al. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. *Alzheimers Dement* 2019, **15**(8): 1071–1080.

[88] Perrotte M, Haddad M, Le Page A, et al. Profile of pathogenic proteins in total circulating extracellular vesicles in mild cognitive impairment and during the progression of Alzheimer's disease. *Neurobiol Aging* 2020, **86**: 102–111.

[89] Jia LF, Zhu M, Kong CJ, et al. Blood neuroexosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage. *Alzheimers Dement* 2021, **17**(1): 49–60.

[90] Goetzl EJ, Abner EL, Jicha GA, et al. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. *FASEB J* 2018, **32**(2): 888–893.

[91] Agliardi C, Guerini FR, Zanzottera M, et al. SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer's disease. *Mol Neurobiol* 2019, **56**(8): 5792–5798.

[92] Gámez-Valero A, Campdelacreu J, Vilas D, et al. Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer's disease and dementia with Lewy bodies. *Transl Neurodegener* 2019, **8**: 31.

[93] Takousis P, Sadlon A, Schulz J, et al. Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid. *Alzheimers Dement* 2019, **15**(11): 1468–1477.

[94] Nagaraj S, Zoltowska KM, Laskowska-Kaszub K, et al. MicroRNA diagnostic panel for Alzheimer's disease and epigenetic trade-off between neurodegeneration and cancer. *Aging Res Rev* 2019, **49**: 125–143.

[95] Wu HZY, Thalamuthu A, Cheng L, et al. Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer's disease and controls. *Alzheimers Research Ther* 2020, **12**(1): 59.

[96] Siedlecki-Wullich D, Català-Solsona J, Fábregas C, et al. Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease. *Alzheimers Res Ther* 2019, **11**(1): 1–11.

[97] de Felice B, Montanino C, Oliva M, et al. MicroRNA expression signature in mild cognitive impairment due to Alzheimer's disease. *Mol Neurobiol* 2020, **57**(11): 4408–4416.

[98] Jain G, Stuendl A, Rao P, et al. A combined miRNA-PiRNA signature to detect Alzheimer's disease. *Transl Psychiatry* 2019, **9**(1): 1–12.

[99] González-Sánchez M, Bartolome F, Antequera D, et al. Decreased salivary lactoferrin levels are specific to Alzheimer's disease. *EBioMedicine* 2020, **57**: 102834.

[100] Carro E, Bartolomé F, Bermejo-Pareja F, et al. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. *Alzheimers Dementia (Amst)* 2017, **8**: 131–138.

[101] Bermejo-Pareja F, del Ser T, Valentí M, et al. Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions. *Alzheimers Dement* 2020, **16**(8): 1196–1204.

[102] Yilmaz A, Ugur Z, Bisgin H, et al. Targeted metabolic profiling of urine highlights a potential biomarker panel for the diagnosis of Alzheimer's disease and mild cognitive impairment: a pilot study. *Metabolites* 2020, **10**(9): E357.

[103] Li YX, Guan SC, Jin H, et al. The relationship between urinary Alzheimer-associated neuronal thread protein and blood biochemical indicators in the general population. *Aging (Albany NY)* 2020, **12**(15): 15260–15280.

[104] Ku BD, Kim H, Kim YK, et al. Comparison of urinary alzheimer-associated neuronal thread protein (AD7c-NTP) levels between patients with amnestic
and nonamnestic mild cognitive impairment. *Am J Alzheimers Dis Other Demen* 2020, **35**: 1533317519880369.

[105] Li YX, Kang MM, Wang HX, et al. Urinary Alzheimer-associated neuronal thread protein is not elevated in patients with subjective cognitive decline and patients with depressive state. *J Alzheimers Dis* 2019, **71**(4): 1115–1123.

[106] Ma LN, Chen J, Wang R, et al. The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment. *J Clin Neurosci* 2015, **22**(4): 649–652.

[107] Xu Y, Shen YY, Zhang XP, et al. Diagnostic potential of urinary monocyte chemoattractant protein-1 for Alzheimer's disease and amnestic mild cognitive impairment. *Eur J Neurol* 2020, **27**(8): 1429–1435.

[108] Zhang YQ, Tang YB, Dammer E, et al. Dysregulated urinary arginine metabolism in older adults with amnestic mild cognitive impairment. *Front Aging Neurosci* 2019, **11**: 90.

[109] Li WW, Shen YY, Tian DY, et al. Brain amyloid-β deposition and blood biomarkers in patients with clinically diagnosed Alzheimer's disease. *J Alzheimers Dis* 2019, **69**(1): 169–178.

[110] Rózga M, Bittner T, Batra R, et al. Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers. *Alzheimers Dement (Amst)* 2019, **11**: 291–300.

[111] Lewczuk P, Gaignaux A, Kofanova O, et al. Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. *Alzheimers Res Ther* 2018, **10**(1): 87.

[112] Willemsen EAJ, van Maurik IS, Tijms BM, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. *Alzheimers Dement (Amst)* 2018, **10**: 563–572.

**Qinyu Peng** received her Bachelor’s degree from Lanzhou University, China, in 2020. Now she is a MD candidate in Wuhan University, China. Her research mainly focuses on the pathogenesis of Alzheimer’s disease. E-mail: 2020283020160@whu.edu.cn

**Zhentao Zhang** graduated from Huazhong University of Science and Technology, China, in 2010, and received his doctoral degree in neurology. Then he received his postdoctoral training in Emory University, USA. He is now a professor and chief physician in the Department of Neurology, Renmin Hospital of Wuhan University, China. His current research interests include Alzheimer’s disease, Parkinson’s disease, etc. His research is supported by grants from the National Science Foundation of China. E-mail: zhentaozhang@whu.edu.cn